Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Triatoma virus recombinante (TrV): nueva plataforma para el desarrollo de vacunas basadas en VLP quiméricas y un potencial biocida contra insectos

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20140519003
Publicado:
09/12/2014
Caducidad:
09/12/2015
Resumen:
Un centro de investigación español, en colaboración con una universidad y fundación, ha desarrollado partículas como virus (VLP) derivadas de TrV. Estas VLP pueden utilizarse como adyuvantes o portadores de epítopo en el desarrollo de vacunas. La invención también incluye el proceso de obtención de TrV infeccioso como agente biológico para controlar vectores de la enfermedad de Chagas. Se buscan empresas interesadas en licenciar la patente.

Details

Tittle:
Recombinant Triatoma virus (TrV): a new platform for the development of chimeric-VLP vaccines and a potential insect biocide
Summary:
A Spanish research Institution in collaboration with a university and foundation has developed virus like particles (VLPs) derived from TrV. These VLPs can be used as adjuvant or epitope carrier for vaccine design. The present invention also relates to a process of obtaining an infectious TrV as a biological agent to control Chagas disease vectors. Companies interested in a patent license are being sought.
Description:
TrV infects several insect species belonging to the Triatominae subfamily (Hemiptera:Reduviidae) commonly known as triatomines or kissing bugs. Triatomines are blood-sucking insects acting as vectors for the transmission of Trypanosoma cruzi, a flagellate protozoan responsible for the Chagas disease, one of the most important endemic diseases in Latin America. The development of a TrV reverse genetics system for the production of infectious TrV could constitutes a major breakthrough in the control of Chagas disease vectors. Likely, this new biocide could also be used against other hematophagous insects.
The possibility of producing TrV-VLPs by a recombinant method using a baculovirus insect cell expression system together with their physicochemical and immunogenic properties provide a potential use of the TrV-VLPs also as epitope carrier for vaccine design.
Advantages and Innovations:
- The TrV-VLPs allow epitope exposure on the internal or external surface of the VLPs by insertion or substitution of amino acids, thus facilitating their recognition by the immune system and/or increasing their immunogenicity.
- TrV capsids are stable along a very wide acidic pH range and after lyophilization.
- Production of TrV-VLPS bearing different epitopes may occur through the expression in insect cells by infection of recombinant baculoviruses.
- Recombinant TrV could also be used as biological agent to control Chagas disease vectors.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European Priority patent have been filed

Partner sought

Type and Role of Partner Sought:
A Company interested in a patent license agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001006 Vacunas humanas